0

Global Pulmonary Embolism Therapeutics Market 2019-2023

  • Published: May 2019
  • Pages: 119
  • SKU: IRTNTR31245
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The global pulmonary therapeutics market will grow by USD 6.9 billion during 2019-2023. This report provides a detailed analysis of the market by RoA (oral and parenteral) and geography (Asia, Europe, North America, and ROW). The report analyzes the market’s competitive landscape and offers information on several companies including Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann-La Roche Ltd., and Johnson & Johnson Services Inc.

Some of the key findings from our pulmonary embolism therapeutics market forecast report are summarized below

Global Pulmonary Embolism Therapeutics Market

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global pulmonary embolism therapeutics industry overview

Lifestyle associated factors such as smoking, overweight, old-age pregnancy, and excessive use of estrogen supplements are some of the major causes of pulmonary embolism. Being overweight reduces mobility and increases blood pressure, increasing the risk of pulmonary embolism. The increased use of supplemental estrogen and hormone replacement therapy often leads to blood clots in the lungs and arteries in women. Moreover, patients with HIV and damaged veins are also at a high risk of developing pulmonary embolism. The high incidence of such risk factors will subsequently drive the need for pulmonary embolism therapeutics, during the forecast period.

The extensive use of regenerative therapies is one of the key trends that will drive pulmonary embolism therapeutics market growth. The treatment choices currently available in the market for pulmonary embolism are symptomatic, which require patients to undergo treatment for long durations. This resulted in the need for advanced curative therapy, inducing researchers to focus on identifying and studying genes that cause pulmonary embolism.  Advancements in studies have also enabled researchers to identify genes that are affected by hereditary and acquired factors. Such factors will result in improvements in the treatment of pulmonary embolism, augmenting the growth prospects of this global market. The pulmonary embolism therapeutics market will register a CAGR of about 9% during 2019-2023.

Top pulmonary embolism therapeutics companies covered in this market research report

The global pulmonary embolism therapeutics market is fairly concentrated. To help clients improve their revenue share, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Key insights provided by this pulmonary embolism therapeutics market analysis report will help companies make informed business decisions.

The report offers a detailed analysis of several leading companies, including:

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.

Pulmonary embolism therapeutics market segmentation based on RoA

  • Oral
  • Parenteral

The oral RoA segment accounted for the largest pulmonary embolism therapeutics market share in 2018. This mainly attributed to the approval of several oral anticoagulants in recent years. Because of benefits such as the less requirement for patient monitoring and the advances in the development of these drugs, the oral RoA segment will continue to account for the largest market share throughout the forecast period.

Pulmonary embolism therapeutics market segmentation based on geography

  • Asia
  • Europe
  • North America
  • ROW

There is a high prevalence of pulmonary embolism in North America. Factors such as increasing obese population and the strong prevalence of HIV in the region further increase the risk of pulmonary embolism. The increasing number of awareness programs from the US Government and various organizations have resulted in the early treatment of pulmonary embolism, driving market growth in the region. The launch of new-age oral anticoagulants is also contributing to the growth of the market in North America.

Key highlights of the global pulmonary embolism therapeutics market for the forecast years 2019-2023:

  • CAGR of the market during the forecast period 2019-2023
  • Detailed information on factors that will accelerate the growth of the pulmonary embolism therapeutics market during the next five years
  • Precise estimation of the global pulmonary embolism therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the pulmonary embolism therapeutics industry across Asia, Europe, North America, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on several vendors
  • Comprehensive details of factors that will challenge the growth of pulmonary embolism therapeutics companies 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY              

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Oral - Market size and forecast 2018-2023
  • Parenteral - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research on anticoagulant antidotes
  • Strategic alliances
  • Extensive research on regenerative therapies

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd. 
  • Johnson & Johnson Services Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO


Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Reports 2019
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>